TTUHSC School of Pharmacy
HomeSOPFaculty & Staff Directory

Faculty & Staff Details

Profile for Paul Trippier, PhD

Paul Trippier

Paul Trippier, PhD

  • Assistant Professor Pharmaceutical Sci Amarillo
Office Phone: 806-414-9245
Mail Address: School of Pharmacy, 1300 S. Coulter
Amarillo TX 79106


Dr. Trippier joined the Pharmaceutical Sciences faculty in September 2012.
He received his undergraduate degree with first class honors in Chemistry and Toxicology at the University of Hull (UK) undertaking undergraduate research on the design and synthesis of novel Angiotensin-converting enzyme inhibitors.
Dr. Trippier received his Ph.D. in 2007 from the University of Oxford (UK) working on the total and diversity orientated synthesis of bioactive natural products. He completed postdoctoral research at The Welsh School of Pharmacy, Cardiff University (UK) in antiviral and anticancer medicinal chemistry.
He joins the School of Pharmacy from Northwestern University, IL where he conducted research in the laboratory of Richard B. Silverman on the synthesis and intracellular target identification of potential new therapeutics for the treatment of neurodegenerative disease.

Selected Publications:

  • Kinarivala N, Trippier PC. Progress in the Development of Small Molecule Therapeutics for the Treatment of Neuronal Ceroid Lipofuscinoses (NCLs). J. Med. Chem. 2016;59:4415-4427.
  • Trippier PC. Selecting good ‘drug-like’ properties to optimize small molecule blood-brain barrier penetration. Curr. Med. Chem. 2016;23:1392-1407.
  • Verma K, Zang T, Gupta N, Penning TM, Trippier PC. Selective AKR1C3 inhibitors potentiate chemotherapeutic activity in multiple acute myeloid leukemia (AML) cell lines. ACS Med. Chem. Lett. 2016;7:774-779.
  • Kinarivala N, Shah K, Abbruscato TJ, Trippier PC. Passage variation in PC12 cells results in inconsistent susceptibility to externally induced apoptosis. ACS Chem. Neurosci. 2016.
  • Kinarivala N, Suh J, Botros M, Webb P, Trippier PC. Pharmacophore elucidation of phosphoiodyn A – Potent and selective peroxisome proliferator-activated receptor b/d agonists with neuroprotective activity. Bioorg. Med. Chem. Lett. 2016;26:1889-1893.